Effect of Glycopyrrolate on Nausea and Vomiting After ERCP Operation

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06045364

Enrollment

130

Registered

2023-09-21

Start date

2023-10-01

Completion date

2024-07-31

Last updated

2024-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nausea and Vomiting

Brief summary

This study aims to determine the role of Glycopyrrolate in preventing postoperative nausea and vomiting of ERCP.

Detailed description

This study is a prospective, double-blind, randomized controlled trial. Patients who meet the criteria of our center and need to undergo ERCP lesion resection will be included and randomly divided into groups. After receiving Glycopyrrolate (experimental group) and Anisodamine (control group), duodenal peristalsis, biliary and pancreatic treatment time and postoperative nausea and vomiting will be observed during therapeutic ERCP. The inhibitory effect of Glycopyrrolate on postoperative nausea and vomiting of ERCP will be analyzed statistically. Main outcome measure: incidence of nausea and vomiting after ERCP Secondary outcome measures: mean duodenal contractions per minute, duodenal spasm frequency and score, ERCP operation time, occurrence of other side effects of medication, remedial medication, and incidence of adverse events

Interventions

DRUGGlycopyrrolate

During induction of anesthesia, 0.2mg Glycopyrrolate was given intravenously

DRUGAnisodamine

During induction of anesthesia,10mg of Anisodamine was given intramuscular injection.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* 1.Adults 18-80 years old 2.ASA :I-III 3.Patients who are able to give informed consent and are currently planning to have the lesion removed or examined at the descending ERCP

Exclusion criteria

1: Use of anticholinergic drugs 2: pregnancy 3: glaucoma 4: Myasthenia gravis 5: Obstructive gastrointestinal diseases 6: Obstructive urinary tract disease (prostatic hyperplasia) 7: Heart disease (coronary heart disease, congestive heart failure) 8: hyperthyroidism 9: Previous history of abdominal or intestinal surgery 10: Chronic renal failure \-

Design outcomes

Primary

Measure	Time frame
Incidence of postoperative nausea and vomiting	Timepoint：24 hours after the ERCP

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026